306 related articles for article (PubMed ID: 23483375)
1. Clearing the air: a review of our current understanding of "chemo fog".
O'Farrell E; MacKenzie J; Collins B
Curr Oncol Rep; 2013 Jun; 15(3):260-9. PubMed ID: 23483375
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-related change in cognitive function: a conceptual model.
Hess LM; Insel KC
Oncol Nurs Forum; 2007 Sep; 34(5):981-94. PubMed ID: 17878127
[TBL] [Abstract][Full Text] [Related]
3. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy.
Ferguson RJ; Ahles TA
Curr Neurol Neurosci Rep; 2003 May; 3(3):215-22. PubMed ID: 12691626
[TBL] [Abstract][Full Text] [Related]
4. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy?
Raffa RB; Duong PV; Finney J; Garber DA; Lam LM; Mathew SS; Patel NN; Plaskett KC; Shah M; Jen Weng HF
J Clin Pharm Ther; 2006 Apr; 31(2):129-38. PubMed ID: 16635046
[No Abstract] [Full Text] [Related]
5. Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Park SB; Goldstein D; Krishnan AV; Lin CS; Friedlander ML; Cassidy J; Koltzenburg M; Kiernan MC
CA Cancer J Clin; 2013; 63(6):419-37. PubMed ID: 24590861
[TBL] [Abstract][Full Text] [Related]
6. A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog').
Raffa RB
J Clin Pharm Ther; 2011 Jun; 36(3):257-9. PubMed ID: 21545608
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-related cognitive dysfunction: current animal studies and future directions.
Seigers R; Schagen SB; Van Tellingen O; Dietrich J
Brain Imaging Behav; 2013 Dec; 7(4):453-9. PubMed ID: 23949877
[TBL] [Abstract][Full Text] [Related]
8. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors.
Mohrmann C; Armer J; Hayashi RJ
J Pediatr Oncol Nurs; 2017; 34(2):106-114. PubMed ID: 27251891
[TBL] [Abstract][Full Text] [Related]
9. The chemo-gut study: investigating the long-term effects of chemotherapy on gut microbiota, metabolic, immune, psychological and cognitive parameters in young adult Cancer survivors; study protocol.
Deleemans JM; Chleilat F; Reimer RA; Henning JW; Baydoun M; Piedalue KA; McLennan A; Carlson LE
BMC Cancer; 2019 Dec; 19(1):1243. PubMed ID: 31870331
[TBL] [Abstract][Full Text] [Related]
10. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research.
Rugo HS; Ahles T
Semin Oncol; 2003 Dec; 30(6):749-62. PubMed ID: 14663776
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicity of the CNS: diagnosis, treatment and prevention.
Ricard D; Soussain C; Psimaras D
Rev Neurol (Paris); 2011 Oct; 167(10):737-45. PubMed ID: 21899866
[TBL] [Abstract][Full Text] [Related]
12. Cognitive Deficits in Breast Cancer Survivors After Chemotherapy and Hormonal Therapy.
Frank JS; Vance DE; Triebel KL; Meneses KM
J Neurosci Nurs; 2015 Dec; 47(6):302-12. PubMed ID: 26447567
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy, neurotoxicity, and cognitive changes in breast cancer.
Dutta V
J Cancer Res Ther; 2011; 7(3):264-9. PubMed ID: 22044805
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives.
Cascella M; Di Napoli R; Carbone D; Cuomo GF; Bimonte S; Muzio MR
Recenti Prog Med; 2018 Nov; 109(11):523-530. PubMed ID: 30565571
[TBL] [Abstract][Full Text] [Related]
15. Lost in the fog: understanding "chemo brain".
Hafner DL
Nursing; 2009 Aug; 39(8):42-5. PubMed ID: 19633502
[No Abstract] [Full Text] [Related]
16. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer.
Jansen CE; Miaskowski CA; Dodd MJ; Dowling GA
Oncol Nurs Forum; 2007 Sep; 34(5):997-1005. PubMed ID: 17878128
[TBL] [Abstract][Full Text] [Related]
17. The (mis)classification of chemo-fog--methodological inconsistencies in the investigation of cognitive impairment after chemotherapy.
Shilling V; Jenkins V; Trapala IS
Breast Cancer Res Treat; 2006 Jan; 95(2):125-9. PubMed ID: 16261398
[TBL] [Abstract][Full Text] [Related]
18. Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.
Doolittle ND; Dósa E; Fu R; Muldoon LL; Maron LM; Lubow MA; Tyson RM; Lacy CA; Kraemer DF; Butler RW; Neuwelt EA
J Clin Oncol; 2013 Nov; 31(31):4026-7. PubMed ID: 24101051
[No Abstract] [Full Text] [Related]
19. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response.
Boykoff N; Moieni M; Subramanian SK
J Cancer Surviv; 2009 Dec; 3(4):223-32. PubMed ID: 19760150
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions.
Ongnok B; Chattipakorn N; Chattipakorn SC
Exp Neurol; 2020 Feb; 324():113118. PubMed ID: 31756316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
